New Testing Reveals Silent Measles Spread in US, Raising Concerns About Elimination Status

The United States reported 2,288 confirmed measles cases in 2025 — the highest annual total in more than three decades [1]. Through mid-April 2026, another 1,136 cases have already been counted [1]. But those numbers, public health researchers now say, represent only the visible fraction of a much larger problem. New molecular evidence from whole-genome sequencing and wastewater surveillance suggests the virus was circulating silently for weeks to months before anyone noticed, calling into question not just the accuracy of US measles surveillance but the country's formal disease elimination status [2].

What the Genomes Reveal

CDC disease detectives and researchers at the Broad Institute have sequenced approximately 1,000 whole genomes of measles viruses collected from patients between January 2025 and January 2026 [3]. Traditional measles genotyping analyzes only a 450-nucleotide fragment (called N450) to classify viruses into broad genotypes. Whole-genome sequencing examines the entire ~16,000-nucleotide genome, capturing mutations that accumulate at a rate of roughly one per every two to four transmission events [3][4].

This granularity has allowed researchers to reconstruct transmission chains with far greater precision. When they analyzed viruses from 165 patients in the large Arizona-Utah outbreak, the molecular clock data indicated that early infections likely started at least six weeks — and possibly as many as 14 months — before the first officially diagnosed case, a 10-year-old boy [2][4]. That gap between actual viral circulation and clinical detection is what epidemiologists mean by "silent spread."

The dominant lineage fueling major outbreaks across Texas, Utah, and South Carolina has been identified as D8-9171, which also circulates in Canada and Mexico [3]. Distinguishing between repeated importations and sustained domestic transmission of this lineage is the central question facing the Pan American Health Organization's Regional Verification Commission when it reviews the US elimination status [5].

Source: CDC

Data as of Apr 17, 2026CSV

Sewage as Sentinel

Alongside genomic sequencing, wastewater surveillance has emerged as a second line of evidence for undetected measles transmission. In January 2025, researchers in Houston detected measles RNA in samples from two wastewater treatment plants, yielding 53 unique sequencing reads mapping to 11 regions of the measles genome with a 99.4% match to genotype B3 [6]. The detections preceded confirmed clinical cases in the area.

In Colorado, an August 2025 wastewater sample recorded the highest concentration documented in the US: 944,000 gene copies per liter, with genomic sequencing confirming genotype D8 [7]. The CDC's National Wastewater Surveillance System (NWSS), originally built for COVID-19 tracking, has been adapted to monitor wild-type measles virus and has detected signals earlier than clinical testing in multiple jurisdictions [8].

A broader research effort — the Coalition for Agnostic Sequencing of Pathogens from Environmental Reservoirs (CASPER) — has collected 1,206 wastewater samples from 27 sites across nine states, covering approximately 13 million people, between December 2023 and December 2025 [9]. The network uses untargeted metagenomic sequencing, meaning it does not search for specific pathogens but sequences all genetic material present, reducing the risk of missing novel or unexpected viral variants.

The Implied Multiplier

In typical non-outbreak years between 2020 and 2023, the CDC reported between 13 and 121 confirmed symptomatic measles cases annually [1]. The question raised by the new testing data is how many additional infections were missed.

Measles has long been understood to produce subclinical or modified infections in people with partial immunity — those who received one dose of MMR vaccine instead of two, or whose vaccine-induced antibodies have waned over time. A 2025 study published in eClinicalMedicine found that 12.2% of vaccinated individuals lacked detectable measles antibodies, a figure that rose to 18.1% among those vaccinated more than two decades earlier [10]. These individuals may become infected without developing the classic rash and high fever that trigger clinical diagnosis, yet they can still shed virus.

No peer-reviewed study has yet published a precise multiplier for US measles undercounting. However, the genomic evidence of transmission occurring six weeks to 14 months before first diagnosis in a major outbreak — combined with wastewater detections preceding clinical cases — suggests the ratio of actual infections to confirmed cases is substantially greater than one-to-one [2][6].

A Vaccination Rate in Steady Decline

The conditions enabling silent spread have been building for years. National kindergarten MMR vaccination coverage has fallen below the 95% herd immunity threshold for five consecutive school years, reaching 92.5% in 2024-2025 [11]. Thirty-nine states now fall below 95%, and 16 states reported rates below 90% — up from just three states in 2019-2020 [11][12].

Source: CDC MMWR

Data as of Dec 31, 2025CSV

At the county level, the share of counties meeting or exceeding the 95% threshold has dropped from 50% pre-pandemic to 28%, leaving only 815 counties at or above the benchmark [12]. An estimated 5.2 million kindergarten-age children live in counties below the herd immunity threshold, up from 3.5 million before the pandemic [12].

The national kindergarten vaccine exemption rate hit an all-time high of 3.6% in 2024-2025, representing nearly 138,000 children [13]. Non-medical exemptions rose from 2.2% to 3.4% over the preceding five years. Idaho leads the country with a 15% non-medical exemption rate, while states range widely: 44 states allow religious exemptions, 15 allow personal belief exemptions, and only four — California, Connecticut, New York, and West Virginia — prohibit all non-medical exemptions [13][14].

Research from RAND has documented that states expanding exemption access have seen measles coverage decline, while states that repealed non-medical exemptions experienced increased vaccination rates [14].

The Elimination Question

The United States was first certified as having eliminated measles in 2000, meaning the country had interrupted endemic — continuously circulating — transmission of the virus [5]. The World Health Organization defines elimination as the absence of endemic measles virus transmission for 12 months or more in the presence of a well-performing surveillance system [15].

Certification and decertification are handled by regional verification commissions. For the Americas, PAHO's Regional Verification Commission reviews national reports, epidemiological and laboratory data, molecular evidence, and field investigations [5]. In November 2025, the Americas region as a whole lost its measles-free designation after the commission concluded that endemic transmission had been re-established in Canada [16].

The US review was initially expected in early 2026 but has been postponed to November 2026 during the commission's regular annual meeting, with the analysis period running from January 20, 2025 [5][17]. The key criterion: if genomic evidence demonstrates continuous transmission of the same viral lineage for 12 or more months within US borders, the country will formally lose its elimination status.

Some epidemiologists argue the elimination framework has always relied on passive surveillance — waiting for sick patients to seek care and be correctly diagnosed — that structurally undercounts silent transmission [2]. Measles has not circulated widely in the US for three decades, meaning many practicing physicians have never seen a case and may miss diagnoses, particularly of modified infections in partially immune individuals [2].

Who Bears the Risk

Undetected measles circulation poses the greatest danger to three populations. Infants under 12 months cannot receive the MMR vaccine and depend entirely on surrounding community immunity for protection [18]. Immunocompromised individuals — including organ transplant recipients, cancer patients undergoing chemotherapy, and people living with HIV — may experience more severe measles, remain infectious for longer than the typical four-days-before to four-days-after rash onset window, and harbor viruses that undergo substantial intra-host evolution [19][20].

A study of 351 participants in a US HIV clinic found a measles seroprevalence rate of only 70.3%, well below the level needed for individual protection [21]. The "cocooning" strategy — ensuring all household contacts and healthcare personnel of vulnerable individuals are vaccinated — remains the primary protective measure for those who cannot receive MMR, but its effectiveness depends on the very community vaccination rates that are declining [18].

What Changed

Several converging factors over the past decade have created conditions for measles resurgence. Declining vaccination rates, driven partly by growing vaccine hesitancy and partly by pandemic-era disruptions to routine childhood immunization, have eroded herd immunity in an increasing number of communities [11][12]. Waning antibody levels in adults vaccinated decades ago have expanded the pool of susceptible individuals [10]. And increased international travel has multiplied opportunities for viral importation from countries where measles remains endemic [1].

Historically, vaccinated populations received periodic immune boosting through exposure to circulating wild-type measles virus. As measles was eliminated from the US, this natural boosting disappeared, potentially accelerating antibody waning [10]. The genomic evidence from viral sequencing adds another dimension: the D8-9171 lineage driving US outbreaks also circulates in Canada and Mexico, suggesting that cross-border transmission chains may be sustaining the virus across North America [3][5].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Counterargument

Vaccine-skeptic critics have seized on the concept of "silent spread" to advance a different interpretation. Their strongest argument: if large numbers of unvaccinated or partially vaccinated people are being infected without developing clinical disease, this demonstrates that the human immune system is containing measles without vaccination-induced immunity. Subclinical infection, they contend, may confer durable natural immunity and should be studied rather than suppressed through coercive vaccination mandates [22].

This argument conflates several distinct phenomena. Subclinical measles infection has been documented primarily in people with partial vaccine-derived immunity — those who received one MMR dose or whose antibodies have waned — not in entirely unvaccinated, immunologically naive individuals [10]. Measles infection in a truly unvaccinated person typically produces severe clinical illness; the case fatality rate in unvaccinated children ranges from one to three per thousand in developed countries and can exceed 5% in malnourished or immunocompromised populations [18]. Modified or subclinical infection in partially immune individuals, while less severe for the infected person, still allows viral shedding and transmission to others, including vulnerable populations [2].

Some vaccine policy critics also raise procedural concerns about whether expanding surveillance capacity — particularly wastewater monitoring and genomic sequencing — is being used to justify new mandates rather than to improve genuine understanding of disease burden [22]. These concerns intersect with broader debates about public health authority, bodily autonomy, and the limits of government power over medical decisions.

The Cost of Restoration

The UK's experience offers a partial roadmap. Britain achieved measles elimination in 2016, lost the designation in August 2019 after endemic transmission was re-established, and regained it in 2021 — aided significantly by COVID-19 pandemic conditions that reduced all respiratory virus transmission [23]. The UK then lost elimination status again in January 2026, based on 2,911 lab-confirmed cases in England in 2024, the highest since 2012 [24]. The underlying cause in both instances was a decade-long decline in routine vaccination coverage that persistently failed to reach 95% [23].

To regain elimination status, a country must demonstrate three consecutive years without sustained domestic transmission, supported by robust surveillance and vaccination coverage data [15][25]. For the US, where the outbreak infrastructure spans 50 states with varying exemption laws, public health capacity, and political dynamics, restoration would require coordinated federal and state action.

Federal authority rests primarily with the CDC, which provides technical assistance, outbreak investigation support, and vaccination program funding through the Vaccines for Children program. But vaccination policy — including school entry requirements and exemption rules — is set at the state level, creating a patchwork of standards [14]. States that have tightened exemption policies have seen coverage rise; states that have loosened them have seen it fall [14]. No federal law mandates childhood vaccination.

The financial cost of a national measles response is substantial. CDC allocated $63 million for measles response activities in fiscal year 2025, but state and local health departments bore significant additional costs for case investigation, contact tracing, and community vaccination campaigns [1]. A full restoration effort — involving targeted catch-up vaccination campaigns in low-coverage communities, expanded surveillance infrastructure, and sustained public communication — would likely require funding well beyond current appropriation levels, though no official cost estimate for such an effort has been published.

What Happens Next

The November 2026 PAHO review will hinge on molecular evidence. If whole-genome sequencing data demonstrate that the D8-9171 lineage or any other measles lineage has circulated continuously within US borders for 12 months, the country will lose its elimination designation [5]. The practical consequences would be largely symbolic — no trade restrictions or international sanctions follow — but the reputational and political impact could be significant, potentially galvanizing either renewed investment in vaccination infrastructure or further polarization of vaccine policy debates.

The broader lesson from the new testing data is that passive surveillance — the system the US has relied on for a quarter century — was not designed to detect the kind of transmission that genomic sequencing and wastewater monitoring are now revealing. Whether that transmission represents a genuine threat to population health or an artifact of more sensitive detection methods is a question that demands rigorous, transparent investigation rather than predetermined conclusions.